134 related articles for article (PubMed ID: 23846930)
1. Biomarkers in neuroendocrine tumors.
Duque M; Modlin IM; Gupta A; Saif MW
JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
[TBL] [Abstract][Full Text] [Related]
2. Update on novel therapies for pancreatic neuroendocrine tumors.
Oberstein PE; Saif MW
JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic neuroendocrine tumors: entering a new era.
Oberstein PE; Remotti H; Saif MW; Libutti SK
JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
[TBL] [Abstract][Full Text] [Related]
5. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
[TBL] [Abstract][Full Text] [Related]
6. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Gupta A; Duque M; Saif MW
JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
[TBL] [Abstract][Full Text] [Related]
7. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
8. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
9. Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors.
Oberstein PE; Saif MW
JOP; 2012 Jul; 13(4):368-71. PubMed ID: 22797391
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
11. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
Franco M; Pàez-Ribes M; Cortez E; Casanovas O; Pietras K
Horm Metab Res; 2011 Nov; 43(12):884-9. PubMed ID: 21960459
[TBL] [Abstract][Full Text] [Related]
12. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
Burney S; Khawaja KI; Saif MW; Masud F
JOP; 2014 Jul; 15(4):313-6. PubMed ID: 25076330
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Oberstein PE; Saif MW
JOP; 2011 Jul; 12(4):358-61. PubMed ID: 21737896
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Xu X; Strimpakos AS; Saif MW
JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in pancreatic adenocarcinoma.
Joza N; Saif MW
JOP; 2014 Jul; 15(4):308-9. PubMed ID: 25076328
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca2+ channels and regulates chromogranin a secretion in BON-1 cells.
Mergler S; Strauss O; Strowski M; Prada J; Drost A; Langrehr J; Neuhaus P; Wiedenmann B; Ploeckinger U
Neuroendocrinology; 2005; 82(2):87-102. PubMed ID: 16424676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
